发明申请
- 专利标题： Novel pyrazinones as CRF1 receptor antagonists
- 专利标题（中）： 新型吡嗪酮作为CRF1受体拮抗剂
-
申请号： US10840484申请日： 2004-05-06
-
公开(公告)号： US20050020601A1公开(公告)日： 2005-01-27
- 发明人: Jeffrey Corbett , Michael Ennis , Robert Hoffman , Patrick Verhoest
- 申请人： Jeffrey Corbett , Michael Ennis , Robert Hoffman , Patrick Verhoest
- 专利权人： Pfizer Inc
- 当前专利权人： Pfizer Inc
- 主分类号： A61P25/00
- IPC分类号： A61P25/00 ; C07D241/20 ; C07D401/04 ; C07D401/14 ; C07D403/12 ; C07D403/14 ; C07D417/14 ; A61K31/497 ; A61K31/4965
摘要：
The present invention provides substituted pyrazinone derivatives of Formula I that are CRF1 receptor antagonists, including human CRF1 receptors. This invention also relates to use of compounds of the invention for treating a disorder or condition, the treatment of which can be effected or facilitated by antagonizing a CRF receptor, such as CNS disorders, particularly anxiety-related disorders and mood disorders.
信息查询
